Flexible funding needed?
Ad-hoc grants
This channel allows EB Resnet and its potential grantholders to remain flexible and to respond in a timely manner to opportunities that arise, such as co-funding options, immediate need for funds, novel project ideas, or proof-of-concept projects.
Academic researchers, clinicians and also industry may approach EB Resnet outside the scheduled research-proposal calls if there is an urgent need or a co-funding opportunity arises. This funding channel is usually only available while no research grant call is open. For example, an international or national funding scheme, a company or another patient group may offer funding schemes that also invite co-funding. Proposals more appropriate to scheduled research grant calls or industry co-funding, will be redirected.
Project scope 'Ad-hoc grants'
- Fundamental to clinical research projects in EB
- Funding/co-funding to respond to opportunities arising in fundamental to clinical research or proof-of-concept projects in EB (including databased initiatives and studies)
- Lead applicant: researchers, clinicians, and/or industry partners (cooperation with industry welcome and possible)
- Project duration: 6 - 36 months
- Funding: up to EUR 90,000.00 p.a.
We are looking for projects that address these unmet medical needs in EB:
- Chronic inflammation and fibrosis
- Pain
- Itch
- Cutaneous squamous cell carcinoma (cSCC)
In addition this scheme welcomes data-led initiatives supporting fundamental to clinical research projects in EB.
Application process Ad-hoc grants
The application process has two steps and is open only on invitation after successful evaluation of an Expression of Interest (EOI) Proposal. Informal application is done via a letter of interest (LOI) to office@eb-researchnetwork.org. As soon as you are invited to submit a project, EB Resnet usually allows 8-10 weeks for submission (exact deadline will be communicated). Received applications will be then subject to external peer review. Decisions on funding applications will usually be made within 6 months after submission deadline.
You will be informed whether your project fits into our funding scheme and if so, sent a link to our Grant Management online Application form.
Ad-hoc grants
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| Ad-hoc 2024/1 | Prof Jemima Mellerio Projectdetails (PEBLES 3) | Kings College London, UK | 12 months | EB genetics, epigenetics & biology | RDEB | LifeArc contracted by DEBRA Austria |
| Ad-hoc 2023/1 | Prof Gudrun Salamon | Sigmund Freud University Vienna, Austria | 24 months | Observational study | all types | DEBRA Austria |
| Ad-hoc 2022/2 | Prof Jemima Mellerio Projectdetails (PEBLES 2) | St. John's Institute of Dermatology & Guy's and St Thomas, UK | 21 months | EB genetics, epigenetics & biology | RDEB | DEBRA Austria |
| Ad-hoc 2022/1 | Prof John Connelly | Queen Mary University of London, UK | 9 months | EB genetics, epigenetics & biology | EBS | DEBRA Austria |
| Ad-hoc 2021/2 | Dr. Ulrich Koller | EB House Austria, Salzburg, Austria | 3 years | Molecular therapy & cellular therapy | RDEB | DEBRA Austria |
| Ad-hoc 2021/1 | Dr. Gudrun Salamon | Siegmund Freud University Vienna | 2 years | Psychology | all | DEBRA Austria |
| Ad-hoc 2020/2 | Dr. Mattew Caley | Queen Mary University London, UK | 2 years | Small molecules | Junctional | DEBRA Austria LifeArc Philantrophic Fund (UK) |
| Ad-hoc 2020/1 | Prof. Dennis Roop, Dr. Ganna Bilousova | University of Colorado, Denver, USA | 3 years | Preclinical | Simplex
| DEBRA Austria Vlinderkindje (B) |
| Ad-hoc 2019/1 | Dr. Thomas Magin | University of Leipzig, Germany | 1 year | Fever in EB | Simplex
| DEBRA Austria Tove Bruce (Sweden) |
| Ad-hoc 2019/2 | DDr. Gudrun Salamon | Sigmund Freud University, Austria | 18 months +1 months Extension | Quality of life, Psychology | Simplex, Dystrophic, Junctional | DEBRA Austria |
| Ad-hoc 2017/1 | Dr. Alexander Nyström, Dr. Leena Bruckner-Tuderman | University of Freiburg - Medical Center, Departement of Dermatology, Germany | 1 year | Preclinical, fibrosis | Dystrophic | DEBRA Austria |
| Ad-hoc 2016/1 | Prof. Dennis Roop | University of Colorado, Denver, USA | 2 years | Preclinical | Simplex | DEBRA Austria Vlinderkindje (B) |
